Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment

Papers of special note have been highlighted as: ▪ of interest

References

• 1  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin.62(1),10–29 (2012).
  Google Scholar
• 2  Pao W, Hutchinson KE. Chipping away at the lung cancer genome. Nat. Med.18(3),349–351 (2012).
  Medline CASGoogle Scholar
• 3  Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat. Rev. Cancer9(8),550–562 (2009).
  Medline CASGoogle Scholar
• 4  Willems L, Tamburini J, Chapuis N, Lacombe C, Mayeux P, Bouscary D. PI3K and mTOR signaling pathways in cancer: new data on targeted therapies. Curr. Oncol. Rep.14(2),129–138 (2012).
  Medline CASGoogle Scholar
• 5  Papadimitrakopoulou V. Development of PI3K/AKT/mTOR pathway inhibitors and their application in personalized therapy for non-small-cell lung cancer. J. Thorac. Oncol.7(8),1315–1326 (2012).
  Medline CASGoogle Scholar
• 6  Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov.8(8),627–644 (2009).
  Medline CASGoogle Scholar
• 7  Benjamin D, Colombi M, Moroni C, Hall MN. Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat. Rev. Drug Discov.10(11),868–880 (2011).▪ Systemic review on mTOR inhibitors.
  Medline CASGoogle Scholar
• 8  Zinzalla V, Stracka D, Oppliger W, Hall MN. Activation of mTORC2 by association with the ribosome. Cell144(5),757–768 (2011).
  Medline CASGoogle Scholar
• 9  Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of AKT/PKB by the rictor-mTOR complex. Science307(5712),1098–1101 (2005).
  Medline CASGoogle Scholar
• 10  Stambolic V, Suzuki A, De La Pompa JL et al. Negative regulation of PKB/AKT-dependent cell survival by the tumor suppressor PTEN. Cell95(1),29–39 (1998).
  Medline CASGoogle Scholar
• 11  Um SH, Frigerio F, Watanabe M et al. Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature431(7005),200–205 (2004).
  Medline CASGoogle Scholar
• 12  Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer2(3),261–274 (2011).▪ Systemic review on how the RAS pathway modulates PI3K.
  Medline CASGoogle Scholar
• 13  Gadgeel SM, Wozniak A. Preclinical rationale for PI3K/AKT/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer. Clin. Lung Cancer14(4),322–332 (2013).
  Medline CASGoogle Scholar
• 14  Tsurutani J, Fukuoka J, Tsurutani H et al. Evaluation of two phosphorylation sites improves the prognostic significance of AKT activation in non-small-cell lung cancer tumors. J. Clin. Oncol.24(2),306–314 (2006).▪ Evaluation of AKT activation in lung cancer.
  Medline CASGoogle Scholar
• 15  Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated AKT overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer51(2),181–191 (2006).
  MedlineGoogle Scholar
• 16  Donev IS, Wang W, Yamada T et al. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin. Cancer Res.17(8),2260–2269 (2011).
  Medline CASGoogle Scholar
• 17  Martini M, Ciraolo E, Gulluni F, Hirsch E. Targeting PI3K in cancer: any good news? Front. Oncol.3,108 (2013).
  MedlineGoogle Scholar
• 18  Wagner AJ, Von Hoff DH, LoRusso PM et al. A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J. Clin. Oncol.27(Suppl. 15), Abstract 3501 (2009).
  Google Scholar
• 19  Shapiro G, LoRusso P, Kwak EL et al. Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: a first-in-human Phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors. J. Clin. Oncol.29, Abstract 3005 (2011).
  Google Scholar
• 20  Besse B, Soria J, Gomez-Roca C et al. 1A Phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC). J. Clin. Oncol.29, Abstract 3044 (2011).
  Google Scholar
• 21  Fruman DA, Rommel C. PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic. Cancer Discov.1(7),562–572 (2011).
  Medline CASGoogle Scholar
• 22  Bendell JC, Rodon J, Burris HA et al. Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J. Clin. Oncol.30(3),282–290 (2012).
  Medline CASGoogle Scholar
• 23  Patnaik A, Appleman LJ, Mountz JM et al. A first-in-human Phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: results of dose-escalation phase. J. Clin. Oncol.29, Abstract 3035 (2011).
  MedlineGoogle Scholar
• 24  Jimeno A, Herbst RS, Falchook GS et al. Final results from a Phase I, dose-escalation study of PX-866, an irreversible, pan-isoform inhibitor of PI3 kinase.. J. Clin. Oncol.28(Suppl.), Abstr 3089 (2010).
  Google Scholar
• 25  Jimeno A, Senzer NN, Rudin CM et al. PX-866 and docetaxel in patients with advanced solid tumors. J. Clin. Oncol.30, Abstract 3024 (2012).
  Google Scholar
• 26  Tabernero J, Saura C, Roda Perez D et al. First-in-human Phase I study evaluating the safety, pharmacokinetics (PK), and intratumor pharmacodynamics (PD) of the novel, oral, ATP-competitive AKT inhibitor GDC-0068. J. Clin. Oncol.29, Abstract 3022 (2011).
  Google Scholar
• 27  Kurzrock R, Patnaik A, Rosenstein L et al. Phase I dose escalation of the oral MEK ½ inhibitor GSK 1120212 dosed in combination with the oral AKT inhibitor GSK 2141795. J. Clin. Oncol.29, Abstract 3085 (2011).
  Google Scholar
• 28  Mack PC, Farneth N, Mahaffey C et al. Impact of AKT inhibitor MK-2206 on erlotinib resistance in non-small cell lung cancer (NSCLC). J. Clin. Oncol.29, Abstract 7573 (2011).
  Google Scholar
• 29  Richardson PG, Eng C, Kolesar J, Hideshima T, Anderson KC. Perifosine, an oral, anti-cancer agent and inhibitor of the AKT pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. Expert Opin. Drug Metab. Toxicol.8(5),623–633 (2012).
  Medline CASGoogle Scholar
• 30  Majumder PK, Febbo PG, Bikoff R et al. mTOR inhibition reverses AKT-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat. Med.10(6),594–601 (2004).
  Medline CASGoogle Scholar
• 31  Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res.64(1),252–261 (2004).
  Medline CASGoogle Scholar
• 32  Beuvink I, Boulay A, Fumagalli S et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell120(6),747–759 (2005).
  Medline CASGoogle Scholar
• 33  O’Donnell A, Faivre S, Judson I. A Phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK) and pharmacodynamic (PD) endpoints in patients with solid tumours. Proc. Am. Soc. Clin. Oncol.22(200), Abstract 803 (2003).
  Google Scholar
• 34  Tabernero J, Rojo F, Burris H et al. A Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR inhibitor RAD001 (RAD001) in patients (pts) with advanced solid tumors. J Clin. Oncol.23(Suppl. 16), Abstract 3007 (2005).
  Google Scholar
• 35  Soria JC, Shepherd FA, Douillard JY et al. Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors. Ann. Oncol.20(10),1674–1681 (2009).
  MedlineGoogle Scholar
• 36  Buck E, Eyzaguirre A, Brown E et al. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol. Cancer Ther.5(11),2676–2684 (2006).
  Medline CASGoogle Scholar
• 37  Papadimitrakopoulou VA, Soria JC, Jappe A, Jehl V, Klimovsky J, Johnson BE. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer. J. Thoracic Oncol.7(10),1594–1601 (2012).
  CASGoogle Scholar
• 38  Price KA, Azzoli CG, Krug LM et al. Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J. Thoracic Oncol.5(10),1623–1629 (2010).
  Google Scholar
• 39  Nogova L, Mattonet C, Gardizi M et al. SORAVE: sorafenib and everolimus for treatment of patients with relapsed solid tumors and with KRAS mutated NSCLC – a Phase I study. J. Clin. Oncol.31(Suppl.), Abstract 8112 (2013).
  Google Scholar
• 40  Khuri FR, Owonikoko TK, Subramanian J et al. Everolimus, an mTOR inhibitor, in combination with docetaxel for second- or third-line therapy of advanced-stage non-small cell lung cancer: a Phase II study. J. Clin. Oncol.29, Abstract e13601 (2011).
  Google Scholar
• 41  Vansteenkiste J, Solomon B, Boyer M et al. Everolimus in combination with pemetrexed in patients with advanced non-small cell lung cancer previously treated with chemotherapy: a Phase I study using a novel, adaptive Bayesian dose-escalation model. J. Thoracic Oncol.6(12),2120–2129 (2011).
  Google Scholar
• 42  Reungwetwattana T, Molina JR, Mandrekar SJ et al. A Phase II NCCTG ‘Window of Opportunity Front-line’ study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC. J. Thorac. Oncol.7(5),919–922 (2007).
  Google Scholar
• 43  Gandhi L, Soria JC, Bryce R et al. Randomized Phase II study of neratinib with or without temsirolimus in patients (pts) with non-small cell lung cancer (NSCLC) carrying HER2-activating mutations. J. Clin. Oncol.31, Abstract TPS8124 (2013).
  Google Scholar
• 44  Westin SN, Melody L. Smart ML, Pal N et al. Phase I trial of sorafenib, bevacizumab, and temsirolimus in advanced solid tumors. J. Clin. Oncol.31, Abstract 2611 (2013).
  Google Scholar
• 45  Pandya KJ, Dahlberg S, Hidalgo M et al.; Eastern Cooperative Oncology Group (E1500). A randomized, Phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500). J. Thoracic Oncol.2(11),1036–1041 (2007).
  Google Scholar
• 46  Haines B, Bittinger M, Chenard M et al. The mTOR inhibitor deforolimus is efficacious in models of mutant KRAS lung cancer. Presented at: American Association for Cancer Research (AACR) Annual Meeting. Denver, CO, USA, 18–22 April 2009 (Abstract 1887).
  Google Scholar
• 47  Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J. Clin. Oncol.26(3),361–367 (2008).
  Medline CASGoogle Scholar
• 48  Taber AM, Khurshid H, Perez K et al. Phase I study of ridaforolimus with cetuximab for patients with advanced non-small cell lung cancer (NSCLC), colorectal cancer, and head and neck cancer. J. Clin. Oncol.31, Abstract 8075 (2013).
  Google Scholar
• 49  Julien LA, Carriere A, Moreau J, Roux PP. mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling. Mol. Cell Biol.30(4),908–921 (2010).
  Medline CASGoogle Scholar
• 50  O’Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT. Cancer Res.66(3),1500–1508 (2006).▪ Release of negative feedback loop by mTORC1 inhibition.
  MedlineGoogle Scholar
• 51  Yu K, Toral-Barza L, Shi C et al. Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin. Cancer Res.69(15),6232–6240 (2009).
  Medline CASGoogle Scholar
• 52  Xue Q, Hopkins B, Perruzzi C, Udayakumar D, Sherris D, Benjamin LE. Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability. Cancer Res.68(22),9551–9557 (2008).
  Medline CASGoogle Scholar
• 53  Tan DS, Dumez H, Olmos D et al. First-in-human Phase I study exploring three schedules of OSI-027, a novel small molecule TORC1/TORC2 inhibitor, in patients with advanced solid tumors and lymphoma. J. Clin. Oncol.28, Abstract 3006 (2010).
  Google Scholar
• 54  Janes MR, Vu C, Mallya S et al. Efficacy of the investigational mTOR kinase inhibitor MLN0128/INK128 in models of B-cell acute lymphoblastic leukemia. Leukemia27(3),586–594 (2013).
  Medline CASGoogle Scholar
• 55  Li S, Li Y, Hu R et al. The mTOR inhibitor AZD8055 inhibits proliferation and glycolysis in cervical cancer cells. Oncol. Lett.5(2),717–721 (2013).
  Medline CASGoogle Scholar
• 56  LoRusso P, Markman B, Tabernero J et al. A Phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors. J. Clin. Oncol.26, Abstract 3510 (2008).
  Google Scholar
• 57  Herrera VA, Zeindl-Eberhart E, Jung A, Huber RM, Bergner A. The dual PI3K/mTOR inhibitor BEZ235 is effective in lung cancer cell lines. Anticancer Res.31(3),849–854 (2011).
  Medline CASGoogle Scholar
• 58  Salkeni MA, Rixe O, Karim NA et al. BEZ235 in combination with everolimus for advanced solid malignancies: preliminary results of a Phase Ib dose-escalation study. J. Clin. Oncol.31, Abstract e13518 (2013).
  Google Scholar
• 59  Sano T, Takeuchi S, Nakagawa T et al. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int. J. Cancer133(2),505–513 (2013).
  Medline CASGoogle Scholar
• 60  Markman B, Tabernero J, Krop I et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors. Ann. Oncol.23(9),2399–2408 (2012).
  Medline CASGoogle Scholar
• 61  Yuan J, Mehta PP, Yin MJ et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol. Cancer Ther.10(11),2189–2199 (2011).
  Medline CASGoogle Scholar
• 62  Owonikoko TK, Khuri FR. Targeting the PI3K/AKT/mTOR pathway. Am. Soc. Clin. Oncol. Educ. Book2013,395–401 (2013).
  Google Scholar
• 63  Di Nicolantonio F, Arena S, Tabernero J et al. Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J. Clin. Invest.120(8),2858–2866 (2010).
  Medline CASGoogle Scholar
• 64  Kwei KA, Baker JB, Pelham RJ. Modulators of sensitivity and resistance to inhibition of PI3K identified in a pharmacogenomic screen of the NCI-60 human tumor cell line collection. PLoS ONE7(9),e46518 (2012).
  Medline CASGoogle Scholar
• 65  Busaidy NL, Farooki A, Dowlati A et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-AKT-mTOR pathway. J. Clin. Oncol.30(23),2919–2928 (2012).▪ Evaluation and management of metabolic effects associated with inhibitors of the PI3K/AKT/mTOR pathway.
  Medline CASGoogle Scholar
• 66  Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J. Clin. Oncol.23(22),5235–5246 (2005).
  MedlineGoogle Scholar
• 67  Lee CK, Marschner IC, Simes RJ et al. Increase in cholesterol predicts survival advantage in renal cell carcinoma patients treated with temsirolimus. Clin. Cancer Res.18(11),3188–3196 (2012).
  Medline CASGoogle Scholar
• 68  Chaft JE, Arcila ME, Paik PK et al. Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Mol. Cancer Ther.11(2),485–491 (2012).
  Medline CASGoogle Scholar
• 69  Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J. Clin. Oncol.28(6),1075–1083 (2010).
  Medline CASGoogle Scholar
• 70  Heavey S, O’Byrne KJ, Gately K. Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC. Cancer Treat. Rev. doi:10.1016/j.ctrv.2013.08.006 (2013) (Epub ahead of print).▪ Systemic review of strategies for cotargeting the PI3K/AKT/mTOR signaling in lung cancer.
  MedlineGoogle Scholar
• 101  ClincialTrials.gov. A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer. http://clinicaltrials.gov/show/NCT01296555
  Google Scholar
• 102  ClincialTrials.gov. A Phase I/IIa, First Time in Human, Study of GSK2636771 in Subjects With Advanced Solid Tumors With Phosphatase and Tensin Homolog (PTEN) Deficiency. http://clinicaltrials.gov/show/NCT01458067
  Google Scholar
• 103  ClincialTrials.gov. MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy. http://clinicaltrials.gov/show/NCT01294306
  Google Scholar
• 104  ClincialTrials.gov. Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC). http://clinicaltrials.gov/show/NCT01147211
  Google Scholar
• 105  ClincialTrials.gov. A Phase 1/2 Trial of Perifosine in the Treatment of Non-Small Cell Lung Cancer. http://clinicaltrials.gov/show/NCT00399789
  Google Scholar
• 106  ClincialTrials.gov. Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors. http://clinicaltrials.gov/show/NCT00777699
  Google Scholar
• 107  ClincialTrials.gov. A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer. http://clinicaltrials.gov/show/NCT00600275
  Google Scholar
• 108  ClincialTrials.gov. A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients. http://clinicaltrials.gov/show/NCT00927823
  Google Scholar
• 109  ClincialTrials.gov. Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer. http://clinicaltrials.gov/show/NCT01347866
  Google Scholar
• 110  ClincialTrials.gov. A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors. http://clinicaltrials.gov/show/NCT01301716
  Google Scholar